Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Gastrointestinal Cancers
•
General Internal Medicine
How do you manage urgency and frequency of bowel movements secondary to radiation proctitis?
Answer from: Radiation Oncologist at Community Practice
In the acute setting we try anusol HC suppository to decrease tenesmus like symptoms
Comments
Radiation Oncologist at Fox Chase Cancer Center
I agree. There’s not a lot of data here, but we ...
609
Sign In
or
Register
to read more
3402
Related Questions
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
How do you counsel patients/families whose goals of care are clearly aligned with a comfort-focused, end-of-life approach, but who are hesitant to formally enroll in hospice?
How likely is late radiation induced lumbosacral plexopathy from treatment of anal cancer with chemo-RT 20 years ago and how would you manage it?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
Would you include the tract in your treatment field in a patient with squamous cell carcinoma of the anal canal presenting with an ano-cutaneous fistula?
What would be your radiotherapy plan for an overall stage IIA, low-lying, MMRd rectal adenocarcinoma to try to avoid APR?
Is there a role for quad-shot or similar regimen in a patient with a technically resectable, but medically inoperable colon cancer that is both bleeding and causing a partial obstruction?
For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative dose for more durable control?
I agree. There’s not a lot of data here, but we ...